Appl. No.: 10/785,577

Art Unit: 1632

Reply to Office Action of 10/03/2007

Patent 1958416.00005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the

application:

Listing of Claims:

Claims 1-16 (CANCELED)

17. (CURRENTLY AMENDED) A tumor cell composition comprising consisting

essentially of a tumor cell modified to express a B7-2 protein and at least one additional

immune modulator, or a functional fragment of said B7-2 protein or said immune

modulator.

18. (PREVIOUSLY PRESENTED) The tumor cell composition according to claim

17, wherein said at least one additional immune modulator is a cytokine protein.

19. (Previously Presented) The tumor cell composition according to claim

18, wherein said cytokine protein is selected from the group consisting of interleukin 2,

interleukin 4, interleukin 6, interleukin 7, interleukin 12, granulocyte-macrophage colony

stimulating factor, granulocyte colony stimulating factor, interferon-gamma, and tumor

necrosis factor-alpha.

20. (PREVIOUSLY PRESENTED) The tumor cell composition according to claim

18, wherein said cytokine protein is granulocyte-macrophage colony stimulating factor.

Claims 21-28 (CANCELED)

29. (WITHDRAWN) A method for the treatment or prevention of cancer

comprising: a) providing a polynucleotide encoding a B7-2 protein and at least one

additional immune modulator, or a functional fragment of said B7-2 protein or said

immune modulator; b) transferring said polynucleotide into cancer cells under conditions

such that said B7-2 protein and said immune modulator are expressed by at least a

portion of said cancer cells; and c) administering an effective amount of the modified

cancer cells of step b) to a patient.

2

Appl. No.: 10/785,577 Patent Art Unit: 1632 1958416.00005

Reply to Office Action of 10/03/2007

30. (WITHDRAWN) The method according to claim 29 further comprising irradiating said cancer cells expressing said B7-2 protein and said immune modulator prior to administering said irradiated cancer cells into said patient.

- 31. (WITHDRAWN) The method according to claim 30, further comprising introducing at least one additional dose of irradiated cancer cells expressing said B7-2 protein and said immune modulator into said immunized subject.
- 32. (WITHDRAWN) The method according to claim 29, wherein said at least one additional immune modulator is a cytokine protein.
- 33. (WITHDRAWN) The method according to claim 32, wherein said cytokine protein is selected from the group consisting of interleukin 2, interleukin 4, interleukin 6, interleukin 7, interleukin 12, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interferon-gamma, and tumor necrosis factoralpha.
- 34. (WITHDRAWN) The method according to claim 32, wherein said cytokine protein is granulocyte-macrophage colony stimulating factor.
- 35. (WITHDRAWN) The method according to claim 29, wherein said polynucleotide is transferred by a viral vector.
- 36. (WITHDRAWN) The method according to claim 35, wherein said viral vector is a retroviral vector.
- 37. (WITHDRAWN) The method according to claim 35, wherein said viral vector is an adenoviral vector.
- 38. (WITHDRAWN) The method according to claim 29, wherein said polynucleotide is encapsulated by, or complexed with, a liposome.
- 39. (WITHDRAWN) The method according to claim 29, wherein said cancer cells are from a solid tumor.
- 40. (WITHDRAWN) The method according to claim 29, wherein said cancer cells are from a brain tumor.

Appl. No.: 10/785,577 Patent Art Unit: 1632 1958416.00005

Reply to Office Action of 10/03/2007

41. (WITHDRAWN) The method according to claim 40, wherein said brain tumor is a glioblastoma.

- 42. (WITHDRAWN) The method according to claim 29, wherein said cancer cells are from a melanoma.
- 43. (WITHDRAWN) A method for the treatment or prevention of cancer comprising administering to a subject in need thereof an effective amount of a tumor vaccine comprising a tumor cell modified to express a B7-2 protein and at least one additional immune modulator, or a functional fragment of said B7-2 protein or said immune modulator.
- 44. (WITHDRAWN) The method according to claim 43, wherein said at least one additional immune modulator is a cytokine protein.
- 45. (WITHDRAWN) The method according to claim 44, wherein said cytokine protein is selected from the group consisting of interleukin 2, interleukin 4, interleukin 6, interleukin 7, interleukin 12, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interferon-gamma, and tumor necrosis factoralpha.
- 46. (WITHDRAWN) The method according to claim 43, wherein said cytokine protein is granulocyte-macrophage colony stimulating factor.
- 47. (WITHDRAWN) The method according to claim 43, wherein said cancer cells are from a tumor.
- 48. (WITHDRAWN) The method according to claim 43, wherein said cancer cells are from a brain tumor.
- 49. (WITHDRAWN) The method according to claim 48, wherein said brain tumor is a glioblastoma.
- 50. (WITHDRAWN) The method according to claim 43, wherein said cancer cells are from a melanoma.